Expertise in
11
conditions

Dr. Jeremie Estepp

Hematology | Oncology
St. Jude Children's Research Hospital
262 Danny Thomas Pl, 
Memphis, TN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
11
conditions
St. Jude Children's Research Hospital
262 Danny Thomas Pl, 
Memphis, TN 

Overview

Jeremie Estepp is a Hematologist and an Oncologist in Memphis, Tennessee. Dr. Estepp is highly rated in 11 conditions, according to our data. His top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Splenectomy, and Adenoidectomy.

His clinical research consists of co-authoring 57 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology
Oncology

Licenses

Pediatrics in TN

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

St. Jude Children's Research Hospital
262 Danny Thomas Pl, Memphis, TN 38105

Additional Areas of Focus

Dr. Estepp has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Investigation of the Genetics of Hematologic Diseases
Investigation of the Genetics of Hematologic Diseases
Enrollment Status: Recruiting
Publish Date: November 04, 2025
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises
Enrollment Status: Completed
Publish Date: December 02, 2025
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis
Enrollment Status: Completed
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drug: Crizanlizumab
Study Phase: Phase 2
A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease
A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease
Enrollment Status: Terminated
Publish Date: August 15, 2025
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants With Sickle Cell Disease (HOPE Kids 2)
Enrollment Status: Terminated
Publish Date: June 13, 2025
Intervention Type: Drug
Study Drug: Voxelotor
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises
Enrollment Status: Terminated
Publish Date: December 11, 2024
Intervention Type: Drug
Study Drug: Inclacumab
Study Phase: Phase 3
Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options
Expanded Access Protocol for Adults and Pediatric Patients With Sickle Cell Disease Who Have No Alternative Treatment Options
Enrollment Status: No_longer_available
Publish Date: November 20, 2024
Intervention Type: Drug
SJTRC-St. Jude Tracking of Viral and Host Factors Associated With COVID-19: A Prospective Adaptive Cohort Study
SJTRC-St. Jude Tracking of Viral and Host Factors Associated With COVID-19: A Prospective Adaptive Cohort Study
Enrollment Status: Completed
Publish Date: August 12, 2024
Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere
Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere
Enrollment Status: Terminated
Publish Date: March 18, 2022
Intervention Type: Drug
Study Drugs: Hydroxyurea, Hydroxyurea Oral Capsule
Study Phase: Phase 2
Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies
Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies
Enrollment Status: Completed
Publish Date: June 25, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

57 Total Publications

Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial.
Mitapivat in adults with non-transfusion-dependent α-thalassaemia or β-thalassaemia (ENERGIZE): a phase 3, international, randomised, double-blind, placebo-controlled trial.
Journal: Lancet (London, England)
Published: November 08, 2024
Similar Doctors
Expertise in
15
conditions
Dr. Marcin Wlodarski
Hematology | Oncology
Expertise in
15
conditions
Dr. Marcin Wlodarski
Hematology | Oncology

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (0.1 miles away)
888-226-4343
Languages Spoken:
English
See accepted insurances

Marcin Wlodarski is a Hematologist and an Oncologist in Memphis, Tennessee. Dr. Wlodarski is highly rated in 15 conditions, according to our data. His top areas of expertise are Aase Syndrome, Pure Red Cell Aplasia, Dyskeratosis Congenita, Bone Marrow Transplant, and Splenectomy.

Expertise in
13
conditions
Dr. Amar Gajjar
Hematology | Oncology
Expertise in
13
conditions
Dr. Amar Gajjar
Hematology | Oncology

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (0.1 miles away)
901-595-2615
Languages Spoken:
English
See accepted insurances

Amar Gajjar is a Hematologist and an Oncologist in Memphis, Tennessee. Dr. Gajjar is highly rated in 13 conditions, according to our data. His top areas of expertise are Medulloblastoma, Embryonal Tumor with Multilayered Rosettes, Glioma, Diffuse Midline Glioma H3 K27M-Mutant, and Posterior Fossa Decompression.

Expertise in
8
conditions
Dr. Jane Hankins
Hematology | Oncology
Expertise in
8
conditions
Dr. Jane Hankins
Hematology | Oncology

St. Jude Children's Research Hospital

262 Danny Thomas Pl, 
Memphis, TN 
 (0.1 miles away)
901-595-4153
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jane Hankins is a Hematologist and an Oncologist in Memphis, Tennessee. Dr. Hankins is highly rated in 8 conditions, according to our data. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemoglobinopathy, Splenectomy, and Adenoidectomy.

Frequently Asked Questions about Dr. Jeremie Estepp

How do I make an appointment with Dr. Jeremie Estepp?

You can book an appointment with Dr. Jeremie Estepp by calling their office at 901-595-3300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jeremie Estepp a top-rated expert for Sickle Cell Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jeremie Estepp is classified as an Elite expert for Sickle Cell Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jeremie Estepp specialize in?

While Dr. Jeremie Estepp is a Hematology, they have specific expertise in Sickle Cell Disease, Congenital Hemolytic Anemia, and Hemoglobinopathy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jeremie Estepp participate in research or clinical trials?

Yes. Dr. Jeremie Estepp has published 57 articles and abstracts on conditions like Sickle Cell Disease. You can view a list of Dr. Jeremie Estepp's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Estepp's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile